Clinical trial
STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not…
NCT00006053 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00006053 |
|---|---|
| Title | STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa |
| Official title | A Study to Determine the Safety and Efficacy of STI571 in Patients With Chronic Myeloid Leukemia Who Are Hematologically or Cytogenetically Resistant or Refractory to Interferon-Alpha, or Intolerant of, Interferon-Alpha |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | imatinib mesylate |
| Start date | Jun 1, 2000 |
| Primary completion | Mar 1, 2003 |
| Completion | Mar 1, 2003 |
| First posted | May 4, 2004 |
| Last update posted | Jan 18, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: